Bertram Graves, MD
Cardiovascular Disease · Indianapolis, INNPI 1821186933
Payments from drug & device makers
Across 346 payments — averaging $40.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Novo Nordisk$2K
- Pfizer$1K
- AbbVie$1K
- Amgen$1K
- plus $4K from 20 others
What the payments were for
- Food & beverage$13,944100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $3,027 |
| GSK | 41 | $1,776 |
| Novo Nordisk | 19 | $1,511 |
| Pfizer | 54 | $1,421 |
| AbbVie(2 entities) | 26 | $1,217 |
| Amgen | 21 | $1,162 |
| Boehringer Ingelheim | 25 | $1,040 |
| Lilly USA, LLC | 34 | $810 |
| Novartis | 10 | $332 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $226 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $183 |
| Otsuka America Pharmaceutical, Inc. | 4 | $168 |
| Merck | 4 | $156 |
| Bayer | 1 | $125 |
| MDD US Operations, LLC | 1 | $125 |
| Sanofi-aventis U.S. LLC | 7 | $124 |
| Biohaven Pharmaceuticals, Inc. | 1 | $123 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Vifor Pharma, Inc. | 6 | $110 |
| Exact Sciences | 4 | $95 |
| Scilex Pharmaceuticals Inc. | 1 | $40 |
| Johnson & Johnson | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,973 in reported general payments places this provider in the 75th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 134 | $156,770 |
| MounjaroTirzepatide | 73 | $83,542 |
| LinzessLinaclotide | 130 | $80,158 |
| TrulicityDulaglutide | 49 | $70,822 |
| OzempicSemaglutide | 70 | $68,641 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $59,764 |
| FarxigaDapagliflozin Propanediol | 73 | $59,135 |
| EliquisApixaban | 69 | $55,958 |
| VraylarCariprazine Hcl | 36 | $51,883 |
| Repatha SureclickEvolocumab | 33 | $45,966 |
| RybelsusSemaglutide | 24 | $41,342 |
| Nurtec OdtRimegepant Sulfate | 27 | $32,277 |
| EntrestoSacubitril/Valsartan | 23 | $25,558 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $18,758 |
| Varenicline Tartrate | 98 | $16,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $1,040 | $167,879147 claims |
| Lilly USA, LLCMounjaro, Trulicity | $810 | $154,364122 claims |
| AbbVieLinzess, Vraylar | $1,217 | $132,042166 claims |
| Novo NordiskOzempic, Rybelsus | $1,511 | $109,98494 claims |
| PfizerEliquis, Nurtec Odt | $1,421 | $88,23596 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,776 | $78,521116 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $3,027 | $78,502106 claims |
| NovartisEntresto | $332 | $25,55823 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $13 | $11,83023 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $40 | $3,52334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Vijay RaoIndianapolis$706K
- Roopa RaoIndianapolis$481K
- Julie ClaryIndianapolis$475K
- James TrippiIndianapolis$449K
- John MillerIndianapolis$354K
- Richard KovacsIndianapolis$338K
- David KovacichIndianapolis$327K
- Jose Emanuel FinetIndianapolis$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.